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Abstract The small-vessel vasculitides are a group of
disorders characterised by variable patterns of small
blood vessel inflammation producing a markedly hetero-
geneous clinical phenotype. While any vessel in any
organ may be involved, distinct but often overlapping
sets of clinical features have allowed the description of
three subtypes associated with the presence of circulat-
ing anti-neutrophil cytoplasmic antibodies (ANCA),
namely granulomatosis with polyangiitis (GPA, formerly
known as Wegener’s Granulomatosis), microscopic po-
lyangiitis (MPA) and eosinophilic granulomatosis with
polyangiitis (eGPA, formerly known as Churg-Strauss
syndrome). Together, these conditions are called the
ANCA-associated vasculitidies (AAV). Both formal
nomenclature and classification criteria for the syn-
dromes have changed repeatedly since their description
over 100 years ago and may conceivably do so again
following recent reports showing distinct genetic associ-
ations of patients with detectable ANCA of distinct
specificities. ANCA are not only useful in classifying
the syndromes but substantial evidence implicates them
in driving disease pathogenesis although the mechanism
by which they develop and tolerance is broken remains
controversial. Advances in our understanding of the
pathogenesis of the syndromes have been accompanied
by some progress in treatment, although much remains
to be done to improve the chronic morbidity associated
with the immunosuppression required for disease
control.
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The small-vessel vasculitides are a group of disorders
characterised by inflammation of the walls of small
blood vessels. The clinical phenotype is extremely het-
erogeneous and reflects the pattern of vessels affected
by inflammation. While any vessel in any organ may be
involved, distinct but often overlapping sets of clinical
features have allowed the description of three subtypes
predominantly affecting small calibre vessels, which are
associated with both the presence of circulating anti-
neutrophil cytoplasmic antibodies (ANCA) and by the
lack of immune complex deposition. These are granulo-
matosis with polyangiitis (GPA, formerly known as
Wegener’s Granulomatosis), microscopic polyangiitis
(MPA) and eosinophilic granulomatosis with polyangiitis
(eGPA, formerly known as Churg-Strauss syndrome).
Together, these conditions are called the ANCA-
associated vasculitidies (AAV). Other forms of non-
ANCA-associated small-vessel vasculitis are typically
characterised by either the presence of immune complex
deposition (for example lupus vasculitis, Henoch-
Schönlein purpura and Goodpasture’s disease) or a
paraneoplastic phenomenon [1].
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Many clinical features are common to all three types
of AAV, including non-specific inflammatory symptoms
such as malaise, fever, anaemia and weight loss, as well
as organ specific involvement such as rash and synovitis.
Differences in clinical features between conditions are
inherently linked to the criteria used to define the con-
ditions. Thus, GPA characteristically has ear, nose and
throat (ENT) and/or respiratory involvement. Necrotising
granulomata may cause sinusitis, nasal discharge, dam-
age to the nasal septum, hearing loss and/or haemoptysis.
eGPA is associated with asthma, eosinophilia and nasal
polyps. MPA commonly affects the kidney without
evidence of granulomata, upper respiratory tract involve-
ment or asthma. The association with ANCA also varies:
80–90 % of individuals with GPA and MPA are ANCA
positive, compared with 40 % of patients with eGPA
(Churg-Strauss). The sensitivity for ANCA in the
diagnosis of GPA (Wegener’s) and MPA is 81–85 %,
whilst the specificity (if assayed by both immunofluores-
cence and ELISA) is 98 % [2]. The type of ANCA varies
with AAV subtype; MPA is predominantly associated
with antibodies to myeloperoxidase (MPO), whilst
patients with GPA are more likely to have antibodies
to proteinase 3 (PR3) [3]. Nonetheless, there is consid-
erable overlap in the classification of AAV [3, 4].
AAV: history
Wegener’s granulomatosis (WG) was arguably first de-
scribed by a Scottish physician, McBride, who in 1897
reported a case of destructive inflammation of the nose
and face which proved rapidly fatal and was pathologically
distinct from infections known to produce similar features,
such as syphilis, tuberculosis and ‘the glanders’ a zoonosis
now known to be caused by Burkholderia mallei (infectious
causes at that time being excluded by inoculation of live
guinea pigs with purulent material) [5]. The first descrip-
tion of any necrotising vasculitis is attributed to Kussmaul
and Meier [6], who described a systemic syndrome includ-
ing kidney and nervous system involvement in 1866,
coining the term ‘periarteritis nodosa’ which persists today
in a revised form (as the increasingly rare vasculitis of
medium-sized vessels, polyarteritis nodosa). Two further
reports, one by Wohlwill in 1923 [7] of vascular inflamma-
tion akin to that seen in what is now termed microscopic
polyangiitis (MPA) and a second by Klinger of granuloma-
tous respiratory tract inflammation with necrotising glo-
merulonephritis in 1931 [8], both precede Friedrich
Wegener’s graduation from medical school in 1932 [9].
Indeed, Wegener himself did not claim the eponym and
was reportedly not keen to use it [10]. Latterly, a movement
proposing that the eponymous title be dropped has
developed following emergence of evidence linking Wege-
ner to the Nazi regime during World War II [11]. It can then
be noted with some irony that it was a Russian Jew, Jacob
Churg (best-known for his description of the related AAV
Churg-Strauss syndrome), who, along with Godman and
after forced emigration to New York city during World War
II, first attributed the condition to Wegener in 1954 [12].
Wegener’s work during the 1930s described a series of
cases in detail [13, 14], but the classification and nomen-
clature of the systemic vasculitides have undergone numer-
ous revisions since.
AAV: changing names and classification
Since the first descriptions by Godman and Churg,
vasculitis has been defined by the calibre of the vessel
involved, with the term ‘microscopic polyarteritis’ used to
distinguish some cases from the earlier descriptions of
periarteritis. The American College of Rheumatology first
published formal criteria for the classification of vasculitis
in 1990 with a reported sensitivity and specificity of 92
and 88 %, respectively for WG, while a definition of MPA
and the use of ANCA were not included [15]. These
criteria were amended in 1994 by the Chapel Hill
Consensus Conference (CHCC) which restricted cases of
WG to those with granulomatous inflammation and intro-
duced microscopic polyangiitis as a novel category to
cover cases without [16]. Also, the concept of surrogate
markers was introduced to aid diagnosis (but not outlined
in detail) which included ANCA, although these were not
incorporated into formal definitions. Sorensen et al. could
not validate the CHCC criteria, finding that only 8/27
patients were accurately classified as having WG and only
3/12 as having MPA [17]. Consequently, they proposed a
further amendment, incorporating biopsy findings which
were purposefully excluded from the CHCC definitions to
facilitate application of the criteria to critically-ill patients
in whom tissue sampling may not be feasible. In turn, the
Sorensen criteria were shown to perform poorly on a
cohort of 99 vasculitis patients with few classified in the
MPA category and many excluded from being WG due to
eosinophilia [18].
Therefore, by 2004, two principal sets of criteria were in
use. The 1990 American College of Rheumatology (ACR)
criteria assigned a classification to most patients but did so
with an unacceptable degree of overlap whereby a single
patient was frequently assigned to more than one diagnos-
tic category (45/99 fitting more than one category in a
validation study [18]). Alternatively, the CHCC criteria
allocated each patient a single category but left an unac-
ceptable proportion as unclassified (37/99 in a validation
study [18]). To resolve this situation, a group of doctors
interested in the epidemiology of vasculitis met at the
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European Medicines Agency in September 2004 and Jan-
uary 2006. They developed a system which, when applied
along with the ACR and Lanham criteria [19] to exclude
CSS, could accurately resolve all cases to a single diagno-
sis (Fig. 1) [20]. The European Medicines Agency
(EMEA) algorithm is optimally employed at least 3 months
after diagnosis, is intended for classification rather than
diagnosis of cases and includes, but does not require,
biopsy evidence of vasculitis and positive ANCA serology
(in practice it is often not possible to obtain biopsy evi-
dence at diagnosis, the inclusion of which risks restricting
classification to a subset of research or referral centres). A
clear list of surrogate features for use in support of a
diagnosis of WG is provided including radiological, histo-
logical and clinical markers of granulomatous upper and
lower airways disease. To confirm that the accurate classi-
fication seen in this description does not derive from
overfitting of a classification model to a relatively small
cohort of patients, the EMEA algorithm has now been
independently validated on a larger cohort of 550 Chinese
vasculitis patients [21]. A further change to the
nomenclature of AAV occurred in 2012, following a sec-
ond Chapel Hill Consensus Conference (CHCC 2012).
Eponyms were replaced where possible with terms consis-
tent with the known pathophysiology of each condition;
hence, Wegener’s Granulomatosis was renamed granulo-
matosis with polyangiitis (Wegener’s) and Churg-Strauss
syndrome was renamed eosinophilic granulomatosis with
polyangiitis. ANCA-negative AAV was also recognised
where a patient otherwise fulfils the definition for an
AAV but has negative results on serologic testing for
ANCA. When referring to ANCA-associated vasculitis as
AAV, CHCC 2012 also recommended that a prefix should
specify ANCA reactivity, i.e. MPO-ANCA, PR3-ANCA or
ANCA-negative AAV [22].
Epidemiology of AAV
The incidence of AAVacross different populations is broadly
similar at 12–18 per million population per year [23, 24]. The
type of vasculitis, however, varies, with GPA being more






















Fig. 1 The changing
classification of AAV (adapted
from Watts et al [20].). A single
cohort of 99 patients with AAV
(from Lane et al [4].) were
assigned diagnostic labels using a
the American College of
Rheumatology 1990 criteria [15],
b the Chapel Hill Consensus
Conference definitions [16] and c
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more common in Spain and Japan [23–25]. The prevalence of
GPA in a predominantly Northern European Caucasian pop-
ulation from New Zealand was similar to that in the UK and
Norway [26]. These population differences in predominant
type of AAV may reflect genetic differences or environmental
factors. The increased frequency in GPA in populations fur-
ther away from the equator may reflect differences in vitamin
D levels, with decreased sun exposure increasing the risk of
developing the disease. Low levels of vitamin D are associat-
ed with the risk of developing other autoimmune diseases
including rheumatoid arthritis, multiple sclerosis and type 1
diabetes [27]. Other environmental risk factors for AAV have
been reported, including infection [28–31], silica [32–34],
livestock [32], high solvent exposure [32], asbestos [35],
pesticides [36] and, more recently, cocaine use contaminated
by the antihelminthic drug levamisole [37].
Ethnic differences may influence both the type and inci-
dence of AAV. Assessment of disease by ethnic distributions
in US cohorts suggested GPA is more prevalent in Caucasians
than African Americans [38, 39]. In New Zealand in 2003, the
5-year incidence of GPA was twice as high in individuals of
European ancestry than in those of New Zealand Maori or
Asian background, whereas Pacific Islanders had a rate ap-
proximately half that of New Zealand Maori or Asian [40]. In
a French multi-ethnic population, AAV was twice as common
in individuals of European, compared with non-European,
ancestry [41], suggesting different degrees of genetic risk.
Genetics, GWAS and reclassification
Reports of multiple family members affected by AAV also
point to genetic risk factors [42, 43]. This degree of risk in
GPA was quantified in a familial aggregation study, which
found a relative risk of 1.56 for first degree relatives of GPA
[44], similar to that seen in rheumatoid arthritis [45, 46]. A
number of candidate gene association studies have been pub-
lished implicating a number of genetic variants, both single
nucleotide polymorphisms (SNPs) and copy number variants
(CNVs) in AAV risk. However, many of these were small and
unreplicated [47–49].
The European Vasculitis Genetics Consortium recently set
out to investigate these genetic risk factors further [50]. Firstly,
a genome-wide association study (GWAS) was performed in a
discovery cohort of 1,233 UK patients with AAV (MPA and
GPA only) and 5,884 UK controls. In the second phase of this
project, single nucleotide polymorphisms (SNPs) that signif-
icantly associated with AAV were genotyped in a replication
cohort of 1,454 Northern European patients and 1,666 con-
trols. In addition, a number of SNPs which had previously
been associated with AAV in candidate gene studies were
examined, even where they had not reached significance in
the discovery cohort, or if they were not represented on the
platform used for the GWAS. Several genetic loci were
significantly associated with AAV, although on subgroup
analysis different associations were identified with GPA
and MPA [50].
Genetic associations within the major histocompatibility
complex
The human major histocompatibility complex (MHC) region
spans 3.6 Mb containing more than 250 genes, more than half
of which have immunological functions. Variants in MHC
have been strongly associated with several autoimmune dis-
eases, including type 1 diabetes [51] and SLE [52]. Prior to the
GWAS, GPA had been associated with an allele encoding
Class II molecule DPB1*0401 (odds ratio (OR) of 3.91, p=
1.51×10−10). In addition, an extended haplotypeDPB1*0401/
RXRB03 showed an even stronger association with GPA (OR
6.41, p=7.13×10−17) [53], raising the possibility of additional
susceptibility loci. This association of the DPB1*0401 allele
with GPA was replicated by a second study, which found a
SNP 3′ of HLA-DPB1 was most associated (p=6.4×10−8),
whilst another SNP in the vicinity of RING1 (which
encodes a transcriptional repressor) also showed a sig-
nificant GPA association that was partly independent of
the HLA-DPB1 effect [54].
The GWAS confirmed the association of AAV with three
SNPs in the MHC. The most significant of these was a SNP in
the gene encodingHLA-DPB1, rs 3117242, (OR 3.67, p value
1.5×10−71). Stepwise logistic regression analysis seeking ef-
fects that were independent of this SNP failed to find addi-
tional distinct susceptibility loci within the MHC [50]. How-
ever, when the data were reanalysed by subgroup, the associ-
ation of HLA-DP was strongest when patients with PR3-
ANCA were compared to control (OR 7.03, p value 6.2×
10−89). In contrast, although the association between this
HLA locus and MPO-ANCAwas much weaker (OR 1.55, p
value 3.2×10−2), MPO-ANCAwas associated with a different
HLA gene, HLA-DQ (OR 0.65, p value 2.1×10−8). Two
previous candidate gene studies have identified an association
between susceptibility to eGPA and HLA-DRB4, whilst HLA-
DRB3 was associated with protection against the disease [55,
56]. Thus, different HLA genes confer varying degrees of
genetic risk across the three subtypes of AAV. A further
GWAS analysis of 492 GPA patients and 1,506 healthy con-
trols performed by the Vasculitis Clinical Research Consor-
tium (VCRC) also identified association with HLA-DP, repli-
cating in a further cohort of 528 cases and 1,228 controls [57].
Genetic associations outside the major histocompatibility
complex
The quantile-quantile plot generated by the GWAS showed
deviation from the null distribution at the extreme end, even
when SNPs in the MHC region were removed, thus non-
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MHC-linked loci also contribute to AAV susceptibility.
Previous studies suggested that variants in the genes
encoding proteinase3 and alpha 1 anti-trypsin confer
risk for AAV.
PR3 is released when activated neutrophils degranulate,
and directly damages endothelial cells—in vitro, the enzyme
causes detachment and cytolysis of endothelial cells. The
cationic enzyme also binds covalently to the endothelium,
where it can bind ANCA and thus trigger antibody-
dependent cytotoxicity [58]. Alpha 1 anti-trypsin (α-1-AT)
is the major inhibitor of PR3 activity, and is thought to limit
the damage done to local tissues. The gene encoding α-1-AT
(SERPINA1) is highly polymorphic, and several of the poly-
morphisms, including the Z and S alleles, reduce the function
of the protein. The decreased function ofα-1-ATmay result in
persistence of PR3 in inflammatory tissue for longer, which
may in turn result in the generation of ANCA. Candidate gene
studies showed an association of the Z and S allele with
cANCA- and pANCA-positive vasculitis, respectively [56,
59], anti-PR3 antibodies [60], GPA [61, 62] or all AAV [63,
64]. Neither anti-PR3 antibodies nor clinical features of GPA
were detected in 191 α-1-AT Z homozygotes [65],
confirming that deficiency in α-1-AT is not enough by
itself to cause GPA.
In the GWAS, the strongest association with AAV
outside the MHC was found at rs 7151526 in the
SERPINA1 locus (OR 0.59, p value 2.4×10−9). This
association was strongest when anti-PR3 was compared
with control (OR 0.53, p value 5.6×10−10), but was not
significant when anti-MPO was compared with control
[50]. The VCRC GWAS also identified an association
with semaphorin 6A (SEMA6A), although this achieved
genome-wide significance in the combined cohorts used
rather than demonstrating independent replication [57].
PR3 is expressed on the surface expression of neutrophils
in a bimodal pattern, with the proportion of neutrophils that
are high or low expressers remaining constant over
time, and unaffected by age or gender [66]. This surface
expression pattern correlates much more closely in
monozygotic (r=0.99) than dizygotic twins (r=0.06),
suggesting that it is genetically determined [67]. Patients
with AAV have an elevated level of membrane bound
PR3 expression, and this is associated with an increased
relapse rate [68, 69]. The gene encoding PR3, PRTN3,
was not well represented on the platform used for the
GWAS, but a previous candidate gene study had shown
an association between a polymorphism in the promoter
region of PRTN3, affecting a putative transcription fac-
tor binding site, and GPA [70]. Thus, a SNP in PRTN3,
rs 62132295, was genotyped by Lyons et al in the
second phase of their study, and was significantly asso-
ciated with PR3-ANCA (OR 0.73, p value 2.6×10−7)
but not MPO-ANCA (OR 1.1, p value 2.2×10−1) [50].
Anti-MPO and anti-PR3 AAVas genetically distinct diseases
Themost striking finding of the GWAS and replication studies
was the disparity between the genetic associations when GPA
and MPA were analysed separately. Patients were classified
with GPA or MPA according to the EMEA algorithm de-
scribed previously [20] and, in addition, patients had to have
either an MPO- or PR3-ANCA, or a diagnostic tissue biopsy
with cANCA or pANCA. For the subgroup analysis, genetic
associations were compared with the diagnoses of GPA or
MPA, as well as with PR3- and MPO-ANCA. As described
above, a SNP in the HLA-DP locus was more strongly asso-
ciated with PR3-ANCA than GPA, but showed no association
with MPO-ANCA. The same pattern of association was seen
with SNPs in SERPINA1 and PRTN3, as well as other SNPs in
other loci e.g. the gene encoding Rho GTPase-activating
protein 18 (ARHGAP18) and the gene encoding motile sperm
domain-containing protein 2 (MOSPD2). One SNP in HLA-
DQ was more significantly associated with MPO-ANCA
compared with PR3-ANCA. However, in the cohorts of pa-
tients recruited to this study, only 489 had MPA (556 had
MPO-ANCA) compared with 1,683 with GPA (1,521 with
PR3-ANCA). This reduced the power of the subgroup analy-
sis to detect associations with MPO-ANCA in particular [50].
Nevertheless, it is clear that there are different genetic contri-
butions to AAVassociated with PR3-ANCA to that associated
with MPO-ANCA, and further studies are planned to address
the genetics of these two conditions separately which may
identify further disease specific genetic susceptibility loci.
There may also be implications for clinical studies that analyse
treatment outcomes for GPA and MPA together, as such
genetically distinct conditions might be expected to have
different clinical courses.
It should be noted that the platforms used for GWAS cover
at best 97 % of the genome, and areas where coverage is poor
are those where there are segmental duplications and exten-
sive copy number variation [71]. Thus, there may be impor-
tant genetic associations with AAV that were not been detect-
ed in the GWAS. For example, previous candidate gene stud-
ies have identified associations with polymorphisms in the
genes encoding Fcγ receptors (for immunoglobulin G) [49],
but this region is very poorly covered by SNP array platforms.
Histopathology of AAV
Histologically, AAV is a necrotising vasculitis with few or no
immune deposits predominantly affecting small vessels (i.e.
capillaries, venules, arterioles and small arteries). Histology is
also critical to the CHCC classification of AAV: in MPA,
necrotising arteritis, glomerulonephritis and capillaritis are
common, but granulomatous inflammation is absent. GPA is
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characterised by necrotising granulomatous inflammation in-
volving the upper and lower respiratory tract. Necrotising
glomerulonephritis, pulmonary haemorrhage and ocular vas-
culitis are also frequently seen in GPA. In eGPA, the
necrotising granulomatous inflammation is eosinophil-rich
and frequently involves the respiratory tract, with ENT in-
volvement often manifest as nasal polyps [22].
All three subtypes of AAV may cause a necrotising glo-
merulonephritis, although this is less common in eGPA, par-
ticularly ANCA-negative eGPA [22]. Renal involvement is
associated with higher morbidity and mortality [72]. A histo-
pathological classification scheme has recently been described
that can prognosticate renal survival [73]. One hundred renal
biopsies were assigned to one of four categories:
1. Focal. >50 % normal glomeruli
2. Crescentic. >50 % glomeruli with cellular crescents
3. Mixed. <50 % normal, <50 % crescentic, <50 % globally
sclerotic glomeruli
4. Sclerotic >50 % globally sclerotic glomeruli
These categories correlated significantly with renal function
at presentation and after 1 and 5 years of follow up. Renal
survival (without end-stage renal disease) at 5 years was 93 %
for the focal class, 76 % for the crescentic class, 61 % in the
mixed category and 50 % in the sclerotic category [73]. Al-
though this classification requires further validation, it may be a
useful tool in predicting renal survival at the time of diagnosis.
The role of ANCA in AAV pathogenesis
Since the initial observation that circulating ANCA character-
ise the condition [74], much debate has centred on whether
and to what extent these autoantibodies might play a role in
disease pathogenesis (Fig. 2).
In vitro evidence
Both MPO and PR3 are typically retained within cytoplasmic
azurophilic neutrophil granules. However, a small proportion
of each is expressed on the neutrophil surface [75] and this is
increased in response to TNFα [76, 77], during apoptosis [78]
and on exposure to ANCA-IgG [76, 77] although expression
is also seen on the surface of monocytes [79].
By contrast with immune complex disorders, AAV is
characterised by so-called ‘pauci-immune’ vascular inflam-
mation, in which immunoglobulin deposition cannot be de-
tected, and the proposed role for ANCA is therefore not of
direct toxicity and tissue damage but of indirect recruitment of
an autoinflammatory response. Neutrophils may be activated
in vitro by ANCA-IgG but only when primed with TNFα [76,
77] in a complex process shown to involve both FcγRIIa-
dependent [80, 81] and independent [82–84] mechanisms.
ANCA-binding may therefore encourage further neutrophil
expression of the autoantigens MPO and PR3, perpetuating
the antigen-specific response. MPO and PR3 also directly
bind to endothelial cells causing direct apoptosis [85] in
addition to that caused by ANCA-activated neutrophils [86]
in an integrin-dependent fashion [87]. Thus, a pathogenic
model has been proposed whereby, in the presence of acces-
sory inflammatory signals (such as LPS or TNFα), neutro-
phils may be further stimulated by circulating ANCA to cause
endothelial toxicity, necrosis and organ dysfunction [88].
In vivo evidence
High circulating titres of ANCA are typically seen during
active disease with subsequent falls during therapy, while
drug-induced forms are accompanied by the appearance of
ANCA which resolve on treatment and removal of the pro-
voking agent [89]. These observations may be consistent with
either a pathogenic role for ANCA but also with the possibil-
ity that ANCA represent an epiphenomenon, accompanying
but not necessarily driving disease. ANCA are not detectable
in approximately 20 % of cases, clinical benefit following B
cell-depleting rituximab therapy is often seen before a signif-
icant reduction in ANCA titre [90] and has also been reported
in ANCA-negative cases [91].
Two reports of newborns who have developed glomerulo-
nephritis and lung haemorrhage within days of delivery to
mothers with circulating anti-MPO antibodies and active vas-
culitis, and responded rapidly to treatment with plasma ex-
change, provide direct evidence of ANCA-related pathoge-
nicity in humans [92]. Animal models also support a patho-
genic role for ANCA. Rats immunised with human MPO
develop anti-MPO antibodies that cross-react with human
and rat MPO, and thus generate a small-vessel vasculitis.
Passive transfer of IgG from these rats into naive rats also
induced disease [93]. Mice do not develop an immune re-
sponse to humanMPO, but MPO-deficient mice injected with
mouse MPO do generate an immune response, such that
injection of anti-MPO IgG from these mice into wild type
mice results in a pauci-immune glomerulonephritis and small
vessel vasculitis comparable to human AAV disease [94].
Transfer of anti-MPO IgG into Rag2−/− mice (that lack func-
tioning lymphocytes) also causes disease, but pre-treatment of
wild type mice with a neutrophil-depleting monoclonal anti-
body is protective, suggesting neutrophils, but not lympho-
cytes, are the main drivers of disease in this model [95]. In
addition, transfer of a T cell-enriched (>99 %) splenocyte
fraction from MPO-immunised MPO−/− mice did not repro-
duce the vasculitis seen after unfractionated splenocyte trans-
fer (a preparation comprising approx 25/65 % T/B cells,
respectively [88]). However, this does not preclude a role for
T cells in disease pathogenesis. The proportion of glomeruli
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showing necrotic changes was substantially higher in the
splenocyte transfer compared to the passive Ig transfer model
(80 vs 15 % crescent formation) although the disease was not




Fig. 2 Histopathology of AAV. All pictures show glomerular lesions
from one patient with an ANCA-associated vasculitis. (Jones-
Methamine-Silver stain, original magnification ×400) a Cellular crescent
involving <50 % of the glomerular tuft defined (according to the histo-
pathologic criteria for AAV [73]) as a lesion filling the Bowman’s space
containing a cellular component of >10%, regardless of the proportion of
the glomerular tuft that is involved (<50% in this picture). The amount of
fibrin or fibrosis does not affect the classification, as long as the required
cellular component is seen. b Cellular crescent involving >50 % of the
glomerular tuft. A case is classified as “crescentic” if ≥50 % of all
glomeruli in the biopsy show crescents (regardless of the proportion
involved in the individual glomerulus). If <50 % of all glomeruli show
crescents, the classification depends on the proportion of normal and
sclerotic glomeruli present in the biopsy: any biopsy with ≥50 % normal
glomeruli is designated as “focal”. In contrast, any biopsy showing ≥50%
of sclerotic glomeruli is classified as “sclerotic” and a biopsy not fulfilling
any of the aforementioned criteria is called “mixed”. cGlomerulus with a
fibrous crescent defined as a lesion filling the Bowman’s space containing
a cellular component of <10%, affecting up to 80% of the tuft. The lesion
is largely composed of fibrous tissue. d Globally sclerosed glomerulus,
>80 % of the tuft is sclerotic. This is not specific for AAV. e Renal
survival (the absence of end-stage renal failure) in a cohort of 82 patients
with AAV by histological classification (from Berden et al.) [73]. Inclu-
sion in the classification schema requires a pauci-immune staining pattern
on immunofluorescence microscopy and at least one glomerulus with
necrotising or crescentic glomerulonephritis on light microscopy
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complex deposition, albeit to a similar degree seen in
control (non MPO-immunised MPO−/−) splenocyte trans-
fer experiments [94].
These studies support a pathogenic role forMPO-ANCA in
AAV. In vivo evidence for anti-PR3 antibodies in disease
causation is less convincing, however. Similar experiments
where PR3-deficient mice are immunised with murine PR3,
then anti-PR3 IgG from these mice is transferred into wild
type mice, does not result in vasculitis of the lung or kidney,
although intravenous injection of anti-PR3 IgG does enhance
panniculitis at sites of subcutaneous TNFα injection [96].
More recently, this model has been enhanced by using an
LPS-primed ‘humanised’ mouse model (irraditated NOD-
scid-IL2Rγ−/− reconstituted with human haematopoietic cells)
in which passive transfer of PR3-IgGANCA from patients did
result in a pauci-immune glomerulonephritis and alveolar
haemorrhage [93].
Additionally, development of disease may require the pres-
ence of a ‘susceptible’ genetic background in addition to
ANCA. The transfer of splenocytes from the autoimmune-
prone NOD mouse after immunisation with recombinant mu-
rine PR3 (rmPR3) generated a necrotising glomerulonephritis
in immunodeficient NOD-SCID recipients but this was not
seen after similar transfer of splenocytes from rmPR3-
immunised C57BL/6 control mice, implicating the
autoimmune-prone background as a critical factor in expres-
sion of a disease phenotype [97].
This proposal could account for observations in humans
that healthy individuals may have ANCA [98] with or without
T cells reactive to either PR3 or MPO antigens [99] without
developing disease.
Complement and AAV
Surprisingly, although deposits of ANCA and immune com-
plexes are not seen in pauci-immune vasculitic lesions, com-
plement may nonetheless play an important role in pathogen-
esis. Adoptive transfer of anti-MPO antibodies can induce a
crescentic glomerulonephritis in recipient mice [94] but dis-
ease is prevented if recipient mice are deficient in components
of the alternative (C5, factor B) but not classical (C4) com-
plement pathway [100] and can be treated (in mice) by
blocking the terminal complement component C5 [101]. In
small cohorts of human AAV patients, alternative complement
components (factor B, properdin) have been reported in in-
flamed vessels [102, 103] with corresponding plasma levels
similarly suggesting alternative pathway activation [104]. It has
been suggested that the higher levels of C5a seen in active AAV
may contribute directly to neutrophil priming as part of an
‘amplification loop’ [105, 106]. The importance of C5 signal-
ling has been shown both in vitro, as C5-stimulated neutrophils
release further C5a [105], and in vivo as C5aR-deficient mice
fail to develop disease in MPO transfer models [106].
Models of broken tolerance in AAV
While ANCA may play a role in driving vasculitis, initial
events leading to a breakdown of tolerance and generation
of autoantibodies have remained unclear. There is increasing
evidence to support the role of bacterial infections as the initial
event that breaks tolerance, resulting in autoimmunity.
Three key hypotheses currently dominate the field.
(1) Anti-idiotype antibodies and complementary PR3
An antibody may recognise the complementarity-
determining region (CDR) of another antibody in what
has been termed an anti-idiotype response [107]. While
investigating PR3 peptides inserted into a bacterial arti-
ficial chromosome expression system, Falk and col-
leagues noted that GPA patient serum reacted to a PR3
peptide which had been inadvertently inserted in reverse.
They postulated that a pathological anti-PR3 response
may develop as an anti-idiotype response to such a
complementary PR3 (cPR3) protein. They subsequently
showed that GPA patients with PR3-ANCA also had
antibodies that could react with this in vitro-generated
cPR3 peptide (and that anti-PR3 could be induced in
naïve mice by immunisation with anti-cPR3 antibody)
[108]. However, these data have not been confirmed in
other patient cohorts [109] and, although widespread
sense-antisense gene pairs have been reported [110],
there is as yet no evidence for in vivo translation of the
cPR3 sequence into peptide. Further research is therefore
necessary before the concept of an anti-idiotypic anti-
body network can be accepted as playing a role in the
pathogenesis of AAV. Indeed, even if this proves to be
the case, cPR3 would still be an endogenous ‘self’ pep-
tide and an explanation for broken tolerance must still be
sought. The peptide sequence of cPR3 has been shown to
have at least partial homology with sequences found in a
range of microbes [108], including Staphylococcus
aureus. However, there is no evidence that anti-cPR3
antibodies cross-react with S. aureus. Furthermore, ro-
dents immunised with S. aureus do not develop AAV
[111], though interestingly immunisation with
Escherichia coli used as a control in this study did induce
AAV in a small proportion of animals. S. Aureus inci-
dence is, however, higher in GPA patients compared to
healthy controls, colonisation is associated with in-
creased relapse rates (relative risk 9.0) [112] and treat-
ment with cotrimoxazole (aiming to eradicate the bacte-
ria) can reduce relapse rates [113].
(2) Anti-LAMP antibodies and molecular mimicry
An alternative hypothesis has been proposed, founded
on principles of molecular mimicry. By probing mem-
brane protein fractions isolated from human neutrophils
and glomeruli with sera fromANCA patients, the protein
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lysosome-associated membrane protein 2 (LAMP2) was
identified as a possible autoantigen [114]. LAMP2 is a
shuttle protein carrying complex oligosaccharides from
lysosomal compartments to the cell surface in neutro-
phils, amongst other cell types, and also plays a role in
intercellular adhesion, through effects on the expression
of E-selectin [115]. Kain et al. showed that circulating
anti-LAMP2 antibodies were present in 78/84 AAV pa-
tients with active glomerulonephritis irrespective of other
ANCA specificities (84 IFANCA+, 38 MPO+, 39 PR3+)
and that autoantibody levels fell with recovery. Intrigu-
ingly, they also demonstrated that rabbit anti-human
LAMP2-IgG (which cross-reacts with rat LAMP2) could
induce a pauci-immune glomerulonephritis on passive
antibody transfer into Wistar Kyoto (WKY) rats and that
LAMP2-IgG could activate primed neutrophils and
cause apoptosis in cultured endothelial cells in much
the same way as the ‘classical’ ANCA MPO- and PR3-
IgG had been shown to do [31]. Furthermore, while
LAMP2 showed no homology with MPO or PR3 (thus
excluding synergy with the anti-idiotype hypothesis), it
showed significant similarity to the sequence of the
bacterial protein FimH, which could induce both
LAMP2-IgG and a pauci-immune glomerulonephritis
on immunisation of WKY rats.
Therefore, infection with a fimbriated FimH-
expressing organism such as E. coli or Klebsiella
pneumoniae could feasibly lead to development of a
pathological anti-LAMP2 response through molecular
mimicry, although this hypothesis also requires further
confirmation, as detection of anti-LAMP2 antibodies in
independent cohorts has been hampered by technical
difficulties with the assay [116]. While molecular mim-
icry by bacterial pathogens may contribute to the devel-
opment of vasculitis, the prevalence of such microbial
infections and the comparative rarity of systemic vascu-
litis indicate that an inherent susceptibility to the break-
down of tolerance must also be required. It should be
noted, however, that the presence of circulating anti-
LAMP2 antibodies remains controversial as, although
the original group have replicated their findings [117],
other groups have not been able to do so [118].
(3) NETosis
Neutrophil extracellular traps (NETs) are structures of
chromatin fibres released by dying neutrophils that trap
and kill extracellular invading microbes [119]. However,
this glutinous DNA web, which contains a number of
antimicrobial peptides includingMPO and PR3, can also
stick to and damage the endothelium of small blood
vessels, causing vasculitis [120, 121]. Even in the ab-
sence of infection, a greater proportion of neutrophils
incubated with purified IgG from patients with AAV
formed NETs compared with neutrophils incubated with
serum from healthy controls. Components of NETs were
identified in close proximity to neutrophils seen in renal
biopsy specimens from individuals with AAV and acute
deterioration of renal function [120]. In vivo, myeloid
dendritic cells uploaded with and activated by NET
components induce ANCA and autoimmunity when
injected into native mice [121].
S. aureus is known to strongly induce NETs [122].
Thus, the propensity of patients with AAV to form NETs
may be exacerbated by infections with this bacteri-
um, which could therefore explain the relationship
between S. aureus and increased relapse risk de-
scribed above (Fig. 3).
T cells in AAV
Tracking the emergence and progression of histological
changes taking place in relatively inaccessible sites, such as
the respiratory tract, is further complicated by the often insid-
ious presentation of the disease resulting in late diagnosis.
This is compounded by the lack of an appropriate animal
model—none of the currently available models develop the
characteristic granulomatous changes of GPA. Despite these
limitations, there is strong evidence to support a key role for T
cells in the aetiopathogenesis of AAV.
T cells in histology
It has been proposed that a localised form of GPA may begin
with extravascular granuloma formation [123]. Biopsy series
suggest that early foci of tissue injury are followed by a mixed
inflammatory cell infiltrate including neutrophils, monocytes,
lymphocytes and, later, epitheloid and multinucleate giant
cells. Mononuclear histiocytes have been observed to sur-
round (or ‘palisade’) a central area of necrosis with the devel-
opment of neutrophilic microabscesses. Such lesions are high-
ly heterogeneous and may be found either adjacent to blood
vessels or at more distant sites [123, 124]. The apparent early
development of these lesions has been suggested to occur in
response to unknown, possibly infectious, immunogens
resulting in a localised phase of disease before tolerance is
broken and systemic manifestations develop. It has long been
appreciated that the infiltration of lymphocytes, particularly
CD3+ T cells, is characteristic of these lesions [125] which
show substantial structural organisation.Myeloid cells (mono-
cytes and neutrophils) expressing high levels of the PR3
autoantigen [126] arrange in clusters and are surrounded by
activated APCs [127], B cells and T cells expressing markers
of effector differentiation [128]. The development of ger-
minal centre-like structures has been observed [129]
with some evidence for T cell-mediated B cell matura-
tion occurring [130]. The predominance of the isotype-
Semin Immunopathol (2014) 36:461–478 469
switched IgG1 and IgG4 subclasses amongst circulating
ANCA is further evidence of T cell help contributing to
the pathological response [131].
Circulating T cells
Measurements of CD4 and CD8 T cell subsets have consis-
tently shown an overall lymphopaenia in AAV [132, 133] with
a reduction in the CD4 to CD8 ratio. It remains unclear,
however, whether this is driven by disease per se or may be
related to concurrent immunosuppressive therapy and whether
it reflects a relative reduction in CD4 counts or an expansion
of CD8 cells. A single, small study suggesting similar changes
prior to therapy [134] and lymphopaenia beyond that seen in
other immunosuppressed cohorts (such as renal transplant
recipients) [132], together imply that it may be a disease-
related phenomenon.
Studies of surface marker expression on circulating CD4 T
cells have identified increased expression of costimulatory
molecules and markers of activation including HLA-DR,
CD137 [135] and CD25 [136, 137] which could not be
explained by altered numbers of the regulatory CD4 subset
(CD4+25+FoxP3+) [132]. Increased CD25 expression was
seen predominantly on CD4 cells with a naïve phenotype
(CD4+CD45RO− [132, 137]), suggesting that these changes
might reflect an inherent increased expression of the activation
marker rather than increased expression due to an activated
phenotype. Associations of polymorphic variants in the IL2RA
gene which encodes CD25 with vasculitis further support this
possibility [138, 139]. While several groups have shown no
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140], others have shown this population to be increased but
with diminished suppressive function in in vitro co-culture
assays with autologous stimulated T cells [133]. Possible
explanations for these contrasting findings include the use of
FoxP3 expression to define a regulatory T cell population, as
this transcription factor can be transiently upregulated follow-
ing human T cell activation [141]. Furthermore, these small
studies incorporated patients with variable levels of disease
activity and therapy at the time of sampling. The association
of increased CD25 expression is a more robust finding, with
increased levels of the soluble form of CD25 also correlating
with disease activity [142, 143]. An increased circulating
Th17 subset (IL-4− IL-17+) has also been reported in the
remission phase [144].
Observations by Kallenberg and colleagues that AAV pa-
tients have increased levels of circulating CD4 TEM cells
(CD4+CD45RO+CCR7−) during remission phase are also
consistent with persistent activation of circulating T cells in
AAV [128, 140]. In one study, a significant decrease in the
circulating proportion of such cells during active renal disease
and their concurrent appearance in urine was shown, consis-
tent with known migratory patterns of effector T cells into
tissues and also with a role for these cells in contributing to the
tissue damage seen [145].
Studies of altered CD8 T cell phenotypic markers in AAV
are less common. One study identified a population of
CD8+CD11b+CD28− cells which was expanded in AAV and
more so in those patients with longer disease duration
(>5 years), although this expansion was not linked to progno-
sis and showed positive correlation with increasing age [146].
T cell function in AAV
Several studies have attempted to identify underlying differ-
ences in T cell responses following in vitro stimulation with
ANCA autoantigens. The direct lymphocyte toxicity of the
Triton-X100 detergent used commercially to isolate protein-
ase 3 from neutrophil azurophilic granules [147] precludes its
use for stimulation studies and confounded some early reports
[148, 149]. Others have attempted to bypass this problem
using detergent-free methods. However, these have not
achieved equivalent purities [150], often with persistent con-
tamination with MPO or other granule contents [151]. The
largest study to date assessed in vitro proliferation of PBMC
cultured with heat-inactivated or native PR3 and MPO in 45
AAV patients at various stages of activity and treatment (16
receiving no immunosuppression). In this study, T cells from
patients showed a significant increase in proliferation com-
pared to healthy controls, although this effect was largely
driven by the responses of a subset of ~20 % of patients,
was seen to be dampened by concurrent therapy, was only
seen with heat-inactivated PR3 (i.e. not with either native PR3
or MPO) and the T cells of healthy individuals also showed
proliferative responses albeit to a lesser degree [150]. Smaller
studies (n=15–21) including patients in remission on no ther-
apy [152] or during active disease with therapy [153, 154]
have shown proliferative responses to native PR3 and MPO,
again in only a subset of patients and again similar prolifera-
tive responses were seen in either healthy or diseased controls
(with either Goodpasture’s disease or IgA nephropathy).
TCR repertoire studies in AAV
An alternative approach to assessing T cell involvement in
AAV has been to profile the Tcell receptor (TCR) repertoire of
circulating Tcells with the hypothesis that over-representation
of T cells bearing a particular TCR variable region may
indicate responses to a common triggering antigen. One study
identified clonal expansion (by restricted CDR3 length) of a
particular Vβ segment (BV8) in circulating CD4 T cells in
four of eight patients that were not seen in either healthy or
disease controls (with RA) [155]. A larger study of 28 patients
with a mixture ofMPA andGPA found over-representation of a
Vβ2.1 junctional region sequence in MPA but not in GPA
patients or healthy controls. This was seen to occur in a poly-
clonal pattern which was interpreted by the authors as possible
evidence of a superantigen effect in which all Vβ2.1 TCR-
bearing T cells may be non-specifically stimulated by bacterial
antigen such as those seen in S. aureus [156]. While S. aureus
carriage is a known risk factor for relapse in GPA [112], a
further, larger study confirmed the presence of specific T cell
expansions in GPA patients but no link with those predicted to
bind staphylococcal superantigens was seen [157].
Strong evidence therefore implicates both CD4 and CD8 T
cells in the pathogenesis of AAV. They are present within
disease lesions, closely apposed to both other T cells, APCs
and B cells to which they are likely to provide help in gener-
ating the isotype-switched high-affinity autoantibodies which
characterise the disease.
Treatment and outcome
The introduction of immunosuppressive therapy has altered
the prognosis of vasculitis, changing it from a frequently fatal
condition (with 1 year untreated mortality rates of approxi-
mately 80 % [158]) to a chronic relapsing and remitting
disease. Five year survival rates are around 75 %, with 1 year
survival rates of 84% [159, 160]. Early predictors of mortality
include infection, leukopenia and cumulative cyclophospha-
mide dose [161], hence infectious complications of immuno-
suppressive therapy now contribute more to morbidity and
mortality than complications of the disease itself [159, 162].
Although therapy successfully induces remission in up to
90 % of survivors [160], 38 % of patients will relapse within
5 years, with GPA being associated with a much higher risk of
relapse thanMPA [163]. New immunosuppressive treatments,
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such as the depleting monoclonal antibody rituximab, promise
to allow induction and maintenance of remission [90] while
limiting infectious complications [164]. Rituximab depletes
CD20+ B cells by antibody-dependent cellular cytotoxicity,
complement-dependent cytotoxicity and apoptosis in an Fcγ
receptor-dependent fashion [165] (Fig. 4). Rituximab was
originally developed to treat non-Hodgkin’s lymphoma, for
which it was licensed by the FDA in 1997, but was then
shown to be an effective treatment for rheumatoid arthritis
and later for AAValso [90]. Two recent randomised controlled
trials in patients with GPA and MPA found that rituximab was
as effective an induction agent as cyclophosphamide, but in
these studies there was no difference in infection rates. In the
rituximab for ANCA-associated vasculitis (RAVE) study,
which recruited relapsing as well as new AAV, rituximab
was more effective at inducing remission in relapsing disease
[166] and this superiority persisted at 12 months [167]. Re-
lapse rates were not significantly different following rituximab
induction therapy with no ongoing maintenance treatment, or
induction with daily oral cyclophosphamide followed by aza-
thioprine maintenance treatment—in both groups, approxi-
mately 30 % of patients had relapsed by 18 months [167].
Retrospective data supports the use of repeated dosing with
rituximab every 6 months for 2 years to maintain remission,
with relapse rates of only 12 % during 24 months of treatment
[168]. There is, however, a risk of hypogammaglobulinaemia
associated with long term treatment with rituximab [169].
Randomised studies of rituximab versus azathioprine as main-
tenance therapy are ongoing.
Given the data presented above on the role of T cells in the
pathogenesis, there is a rationale to target T cells, or at least T
cell help, to treat AAV (an often-overlooked result of B cell
depletion also). Alemtuzumab is an anti-CD52 monoclonal
antibody that depletes mature lymphocytes. It has been used to
treat refractory AAV—a retrospective series from Cambridge
UK described 71 patients with relapsing or refractory disease,
of whom 85 % achieved remission following treatment with
alemtuzumab. However, mortality and morbidity were high—
28 patients developed infection, and 31 patients died at a
median of 106 months [170]. Nonetheless, the patient in this
cohort had previously been heavily immunosuppressed for
refractory disease (median cyclophosphamide dose 150 g)—
and given this, alemtuzumab remains a potential alternative
therapy that warrants further investigation. Another biologic
therapy that shows promise in GPA is abatacept. This fusion
protein combines the Fc region of IgG1 with the extracellular
domain of CTLA, and blocks costimulation of T cells. It is
licensed in the USA for treatment of rheumatoid arthritis, and
is currently being trialled for lupus nephritis in combination
with cyclophosphamide. An open label trial of abatacept in
non-severe GPA found that 80 % achieved remission at a
median of 1.9 months [171]. Thus, therapy targeted to T cells,
as well as B cells, may be effective in AAV, although no
randomised trials have yet been done in this area. The mor-
bidity, mortality and toxicity arising from the immunosuppres-
sion required to control AAV could be alleviated if biomarkers
were available to allow targeting of their use to those with
most severe prognoses.
A recent systematic review of the literature was conducted
by the EULAR systemic vasculitis task force to identify and
assess the quality of outcome measures in vasculitis [72]. The
level of disease-related damage (assessed by the Vasculitis
Fig. 4 Mechanisms of B cell
depletion with rituximab therapy
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Damage Index, VDI) was found to inversely correlate with
successful remission (RR 1.53) while, curiously, those with
higher levels of disease activity (measured by the Birmingham
Vasculitis Activity Score, BVAS, >23) were found to more
easily achieve remission (RR 2.94), independent of the inten-
sity of induction therapy.
Relapse was associated with three independent fac-
tors, firstly, with the level and duration of induction
therapy (<10 g cyclophosphamide within 6 months,
RR 2.83, prednisolone dose >20 mg/day for at least
2.75 months, RR 2.41, and the use of trimethoprim/
sulfamethoxazole RR 0.32), secondly, with target organ
involvement (increased for cardiac, OR 2.87 or renal
involvement with CrCl<60 ml/min, OR 2.94 and also
for chronic nasal carriage of S. aureus, RR 7.16) and
thirdly, with the presence of ANCA. Both the presence
of ANCA at diagnosis (RR 2.89) and also a rise in
PR3-ANCA titre of more than 4-fold (RR 42.5) were
associated with subsequent relapses. This is supported
by long term follow up data from four European treat-
ment trials of 535 patients with GPA or MPA followed
for a total of 1,804 patient years. This study showed
that PR3-ANCA is associated with a higher risk of
relapse than MPO-ANCA (HR1.62 (95 % CI 1.39–
1.89). This was also seen in the 18-month follow up
from the RAVE study comparing rituximab induction
therapy with cyclosphosphamide followed by azathio-
prine, risk factors increasing relapse risk included a
diagnosis of GPA, anti-PR3 ANCA and a previous
history of relapse. Patients with all three risk factors
were at highest risk of relapse (approximately 50 % at
18 months in both treatment groups) [167]. This data
suggests that the type of AAV and ANCA should be
considered when planning the duration and type of
remission [163] therapy, although this has not been
addressed by any prospective clinical trials.
Predicting outcome and targeting therapy in AAV
The development of immunosuppressive therapy has changed
AAV from a progressive and often-fatal disease, into one that
follows a chronic, relapsing-remitting course. However, prog-
nosis is highly variable and current clinical tests—including
ANCA—do not allow prediction of subsequent clinical out-
come. We have found that patterns of gene transcription
within CD8 T cells, measured in patients presenting at
diagnosis before treatment has begun, are able to iden-
tify a subgroup of patients at high risk of subsequent
relapse [172]. This observation has the potential to at
once identify novel pathways for treatment of disease
and the patients in whom such treatment is required.
Similar patterns have been shown to predict clinical
outcome in multiple autoimmune and inflammatory
conditions [173] suggesting that factors controlling re-
lapse and outcome are shared between diseases and are
independent of the mechanism or self-antigen that
breaks tolerance in the first place.
Summary/conclusions
The ANCA-associated vasculitides are rare disorders with
high mortality and morbidity attributable not just to the dis-
ease but the toxicity of current treatment regimes. This toxicity
is compounded by the long duration of treatment required to
minimise relapse risk. Recent research has focussed on ways
to reduce this treatment burden, both by better understanding
of disease pathogenesis to target immunosuppression more
selectively and by identification of biomarkers that identify
patients at an increased relapse risk. Over the last 20 years, a
number of clinical trials have established treatment pathways
for GPA and MPA, with these diseases being treated in a
similar fashion. Long term follow up of these studies, howev-
er, have shown that relapse risk differs between the two
conditions, with GPA, and independently PR3-ANCA, being
markers of increased relapse risk. Genetics studies have also
highlighted the difference between GPA and MPA, and it is
perhaps now time to consider different strategies to treat, and
in particular prevent relapse, in the two diseases. The discov-
ery of novel biomarkers that predict relapse risk across mul-
tiple autoimmune diseases may further pave the way for
personalised medicine, where treatment is tailored to an indi-
vidual’s specific relapse risk, to minimise treatment toxicity.
Clinical trials allowing such flexibility of treatment regimes
will be particularly challenging in rare diseases like the
ANCA-associated vasculitides, but stratification according to
biomarkers, together with a commitment from clinicians to
recruit as many patients as possible to multi-centre interna-
tional clinical trials, may make this possible.
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